Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312151 · ClinicalTrials.gov registry record · Phase 2
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
A Phase 2 study, sponsored by COMPASS Pathways.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT05312151 is a Phase 2 study that has completed, run by COMPASS Pathways. The registered enrollment target is 22 participants.
The verdict
NCT05312151, a Phase 2 study, has completed, sponsored by COMPASS Pathways.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2024-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05312151
The ClinicalTrials.gov registry entry for NCT05312151 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is COMPASS Pathways, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT05312151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05312151 about?
NCT05312151 is a clinical study titled "The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder". The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder
What is the current status of trial NCT05312151?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2022-06-10. Estimated completion is 2024-02-12.
What interventions are being tested in trial NCT05312151?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05312151?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.